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Abstract
Background: Assisted Reproductive Technology (ART) has undergone considerable changes over the last decade,
with consequences on ART outcomes in different regions of the world being unknown.
Methods: We conducted a systematic review of published national and regional ART registry data to assess how
changes in clinical practice between 2004 and 2013 have impacted outcomes in Australia and New Zealand,
Canada, Continental Europe, the United Kingdom (U.K.), Japan, Latin America, and the United States (U.S.). The data
reflect 7,079,145 total ART cycles utilizing both fresh and previously cryopreserved embryos from autologous
oocytes that resulted in 1,454,724 live births. This review focused on the following measures: ART cycle volume, use
of cryopreserved embryos, single embryo transfer (SET), live birth rates in fresh and frozen-thawed cycles, and
perinatal outcomes in recent years.
Results: SETs and utilization of frozen-thawed embryos increased worldwide over the study period. In 2012 SET
utilization in all ART cycles was highest in Japan and Australia/New Zealand (82.6% and 76.3% respectively) and
lowest in Latin America (16.0%). While gradual improvements in live birth rates were observed in most regions,
some demonstrated declines. By 2012–2013, fresh cycle live birth rates were highest in the U.S. (29%) and lowest in
Japan (5%). In Japan, the observed decline in fresh cycle live birth rate coincided with transition to minimal
stimulation protocols, transfer of frozen-thawed rather than fresh embryos, and implementation of an SET policy.
Similarly, implementation of an SET policy in parts of Canada was followed by a decline in fresh cycle live birth rate.
Increasing live birth rates in frozen-thawed embryo cycles, seen all over the world, partially compensated for
declines in fresh ART cycles. During 2012–2013 Australia/New Zealand and Japan reported the lowest multiple
delivery rates of 5.6 and 4% respectively while the US had the highest of 27%. In recent years, preterm delivery
rates in all regions ranged between 9.0 to 16.6% for singletons, 53.9 to 67.3% for twins, and 91.4 to 100% for triplets
and higher order multiples. Inconsistencies in the way perinatal outcome data are presented by various registries,
made comparison between regions difficult.
Conclusions: ART practices are characterized by outcome differences between regions. International consensus on
the definition of ART success, which accounts for perinatal outcomes, may help to standardize worldwide ART
practice and improve outcomes.
Trial registration: PROSPERO (CRD42016033011)
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Background
The last decade has witnessed a number of new treat-
ments integrated into routine assisted reproductive tech-
nology (ART) practice, at times making public outcome
reporting more challenging and less transparent [1, 2]. A
number of new IVF practice regimens have been applied
differently over the world and beg for further critical
evaluation including use of routine blastocyst-stage in
place of cleavage-stage embryo transfer [3] replacement
of fresh embryo transfer by embryo cryopreservation
(“freezing”) and subsequent thawed embryo transfer [4],
preimplantation genetic screening (PGS), [5] single em-
bryo transfer (SET) in place of double embryo transfer
(DET) [6] and minimal stimulation protocols [7, 8]. At
times spurred by government policies or local recom-
mendations of professional societies, adoption of some
practice changes occurred faster in some parts of the
world than others. The most recent worldwide report on
ART practices was authored by the International Com-
mittee for Monitoring Assisted Reproductive Technol-
ogy (ICMART), and was based on data from 2008
through 2010 [9].
Here we examined longitudinal data, reported by ART
centers between 2004 and 2013 to regional registries
worldwide. Our objectives were to study longitudinal
changes in ART practice over the last decade of reported
data, including cycle volumes, use of previously cryopre-
served embryos and of SET. In addition, we assessed
ART outcomes, based on live birth rates in fresh and
frozen-thawed cycles. By comparing practice patterns
and outcomes across regions, as well as longitudinal
changes within regions, this review offers insights into
the global evolution of ART practice.
Methods
This systematic review was exempted from IRB approval
because only publically available de-identified data were
used for the analyses.
Search strategy and data collection
This systematic review was registered with PROSPERO
(CRD42016033011) and is reported in accordance to
PRISMA (Additional file 1: Figure S1, checklist). We sys-
tematically examined aggregate data publically available
from national and regional ART registries since 2004.
ART registries were identified primarily via member and
associated fertility societies of the International Feder-
ation of Fertility Societies [10].
In order to standardize aggregate data from different
regions, we only included reports which allowed calcula-
tion of number of live births per initiated fresh autolo-
gous ART cycles (i.e. utilized the patient’s own oocytes)
over multiple years between 2004 and 2013. In all we
were able to identify ten ART registries with publically
available data. Annual regional ART registry reports
which permitted calculation of live birth per initiated
cycle were identified for seven registries: Australia and
New Zealand combined, [11] Canada, [12] Continental
Europe, [13] the U.K., [14] Japan [15] Latin America [16]
and the U.S. [17] (Table 1). Three other registries (South
Korea, [18] Israel, [19] and South Africa [20]) did not
permit this calculation, and were therefore excluded
from assessment. Live birth rates in frozen-thawed ART
cycles are calculated per initiated cycle for all regions ex-
cept Latin America which reports data per embryo
transfer and Europe which reports data per thaw proced-
ure. Frozen-thawed ART cycles were undertaken for
various indications including cryopreservation of surplus
embryos following a fresh transfer, as well as, embryo
banking for PGS, due to ovarian hyperstimulation and
fertility preservation. These cycles were analyzed to-
gether since specific indications could not be determined
from the registry data.
Data quality and validation
The data in Australia and New Zealand Assisted
Reproduction Database (ANZARD) are self-reported by
fertility centers, and validated by the National Perinatal
Table 1 Total number of ART cycles and live births reported for each region
Fresh Embryo Cycles Frozen Embryo Cycles Live Births
Australia and New Zealanda 357,494 207,678 101,012
Canadaa 111,417 44,707 37,373
Europec 1,959,613 605,673 548,889
Japanb 1,199,715 585,670 224,170
Latin Americaa 265,316 51,047 65,849
UKd 335,438 78,730 101,364
USa 995,410 281,237 376,067
Total 5,224,403 1,854,742 1,454,724
7,079,145
Data for years: a2004–2013, b2004–2012, c2004–2011, d2006–2013
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Epidemiology and Statistics Unit (NPESU), with data
queries being followed up with fertility center staff. [11]
Reporting of ART cycles in Australia is a requirement
for fertility centers to be licensed by the Reproductive
Technology Accreditation Committee. The Fertility So-
ciety of Australia helps ensure the quality of data by
validating selected records against clinic files during
annual inspections. In 2012, ART data were collected
from 37 fertility centers. Outcomes were not provided
for only 1.6% of clinical pregnancies which were lost
to follow up.
Participation of fertility centers in the Canadian
Assisted Reproductive Technologies Register (CARTR)
is voluntary [12]. In 2012, 32 out of 33 centers in Canada
submitted data to CARTR where they were manually
checked for accuracy, and clarifications were requested
from centers. No on-site data validation from source
documents was performed.
Data for 2011 from Europe comes from 33 out of 51
countries, and a total of 1064 fertility centers. Among
these 33 countries, 17 reported complete data sets, and 16
only partial ones [13]. Reporting was compulsory for 17
countries and voluntary for 16. Data were collected in 14
countries by a National Health Authority, in 17 by a Med-
ical Organization, and in 2 by private initiative. Only 13
countries reported some kind of data validation process.
European reports include data from the U.K., which
we here analyzed and reported separately. The 2013 data
from the U.K. was reported under legal mandate by 78
fertility centers to the Human Fertilization and Embry-
ology Authority (HFEA), which validated the data [14].
The Japan Society of Obstetrics and Gynecology (JSOG)
has required all centers that perform ART to register
cycle-specific information since 2007 [15]. In 2012, 586 of
589 (>99%) registered ART centers reported data.
The 2013 report from Latin American Registry of
Assisted Reproduction (RLA) is based on voluntarily re-
ported data from 158 institutions in 15 countries, cover-
ing more than 80% of ART cycles performed in the
region [16]. Patient data from this region have been col-
lected and validated since 2010. Earlier RLA reports
were based on summary data obtained from participat-
ing fertility centers in 12 countries.
The 2012, U.S. source data were self-reported by 456
fertility centers under legal mandate to the Centers for
Disease Control and Prevention (CDC), and covered
more than 97% of all ART cycles performed in the coun-
try [17]. Select on-site annual validation visits including
chart reviews have found low discrepancy rates (<5%)
for most variables in recent years.
Outcome measures
This study includes analysis of longitudinal trends in
volume of fresh and frozen-thawed autologous ART
cycles, as well as, utilization of SET for each region. The
primary outcomes of interest were live birth rates in
fresh and frozen-thawed cycles, calculated for each re-
gion for each year of available data. Additionally, peri-
natal outcomes were reviewed for the recent years of
registry data. Live births included single and multi-fetal
deliveries. Our interpretation of findings refers to abso-
lute differences in data within and between regions; stat-




Figure 1a demonstrates that the volume of ART cycles in
most studied regions moderately increased. The only ex-
ception was Japan where cycle volume nearly tripled dur-
ing the study period. As Fig. 1b demonstrates, utilization
of previously cryopreserved embryos increased in all
a
b
Fig. 1 a Total volume of autologous oocyte ART cycles for study
period 2004–2013. The figure demonstrates gradually increasing ART
cycle number in most regions, except for Japan, which
demonstrates a rapid increase in cycle number. European cycle
volume fluctuated depending on number of reporting countries in
that region each year. b Proportion of ART cycles which utilized
frozen-thawed embryos created from autologous oocytes. The figure
demonstrates that utilization of previously cryopreserved embryos
has increased in all regions except Australia/New Zealand
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regions except Australia/New Zealand, where already a
decade ago such cycles were more common than in any
other region, accounting for more than 35% of all ART.
Single embryo transfer (SET)
In fresh ART cycles, SET utilization increased in all re-
gions (Fig. 2), now representing more than half of all
ART cycles in Japan and in Australia/New Zealand.
Utilization of SET in frozen-thawed ART cycles, likewise,
increased over the study period in the four regions
which reported this data. In Australia and New Zealand
SET in frozen-thawed ART cycles increased from 45.3%
in 2004 to 84.9% in 2013; in Japan from 55% in 2007 to
80% in 2012; in Latin America from 10% in 2008 to
19.9% in 2013; and in Canada from 18% 2004 to 55.2%
in 2013. In Canada SET utilization in both fresh and
frozen-thawed ART cycles increased rapidly following
implementation of a SET policy in Quebec in 2009.
ART live birth rates
Live birth rates in fresh ART cycles varied considerably
between regions. By 2012–2013, the last years for which
national data have been reported, they were highest in
the U.S. (29%) and lowest in Japan (5%) (Fig. 3a).
In fresh ART cycles, live birth rates in most parts of
the world remained flat or minimally increased. Likely
the most remarkable finding of this part of the study
was the precipitous decline in fresh cycle live birth rates
in Japan between 2004 and 2012 (Fig. 3a). During this
period utilization of SET increased in Japan as demon-
strated in Fig. 2; additionally, the practice in that country
transitioned away from fresh embryo transfer and to-
ward transfer of frozen-thawed embryos as demon-
strated in Fig. 1b [7, 8, 21]. By 2012, only 27% of all
ART live birth in Japan were from fresh cycles and 73%
were from frozen-thawed cycles.
That increasing utilization of SET may be associated
with declining live birth rates is also suggested by the
combined data set from Australia/New Zealand, where
live delivery rates per initiated fresh cycle gradually de-
clined to 16.3% in 2013 [11]. Similarly, starting in 2009,
a government mandated SET practice was implemented
in the populous Canadian province of Quebec (Fig. 2);
this was followed by a progressive decline in fresh cycle
live birth rate during subsequent years (Fig. 3a) [22, 23].
Another notable finding was improvement over the
study period in fresh cycle live birth rates in continental
Europe. Indeed, by 2010, continental Europe for the first
time caught up to U.S. rates. Because continental
European data represent an amalgam of many different
nations, cumulative European data are the most difficult
to interpret. While SET practice rose in Northern
Europe [24], its utilization in the whole of Europe still
appears lower than in Australia/New Zealand, Japan and
Canada (Fig. 2a).
During the entire study period live birth rates in
frozen-thawed embryo cycles were highest in the U.S.
(Fig. 3b). Starting in 2009, live birth rates in frozen-
thawed embryo cycles also increased rapidly in the U.S.
This increase in live birth rates was far more pro-
nounced in frozen-thawed than fresh cycles. These ob-
servations, however, have to be interpreted with caution
Fig. 2 Proportion of autologous fresh embryo cycles in which SET was used. The figure demonstrates increasing utilization of SET in all
studied regions
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due to increased utilization of embryo banking in the
U.S. in recent years, [25] which may have distorted ART
outcome reporting [2, 26].
Live birth rates with frozen-thawed embryos increased
all over the world. Indeed, in many regions live birth
rates in frozen-thawed embryo cycles either approached
or surpassed those achieved in fresh ART cycles. For ex-
ample, in Australia/New Zealand improvements in em-
bryo cryopreservation along with increased utilization of
embryo banking led over the past five years to increased
live birth rates in frozen-thawed embryo cycles (from
18.3 to 23.4%), now matching in that region reported
live birth rates following fresh embryo transfer [11].
Interestingly, while fresh ART live birth rates clearly im-
proved in continental Europe, they did so to a much
smaller degree in frozen-thawed embryo cycles.
Perinatal outcomes
In their annual ART reports, Australia/New Zealand and
Canada emphasize perinatal outcomes, including mortal-
ity, gestational ages and birthweights. Reports from
Australia/New Zealand emphasize live born singletons at
term, with normal birthweight as the main outcome
metric for ART [11]. Increasing use of SET in Australia/
New Zealand has been credited with reducing ART mul-
tiple births from 8.2% in 2009 to 5.6% in 2013. In 2013
a
b
Fig. 3 a ART live birth rates with fresh embryos created from autologous oocytes. The figure demonstrates stable or slightly decreasing live birth
rates in most regions. Increasing live birth rates are noted in continental Europe while most pronounced decreases are noted in Japan and in
Canada after 2009. b ART live birth rates with frozen-thawed embryos created from autologous oocytes. The figure demonstrates improving live
birth rates in frozen-thawed cycles in all regions. Data is reported per initiated cycles for all regions except Latin America which reports data per
embryo transfer and Europe which reports data per thawing procedure
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Australia/New Zealand reported a multiple delivery rate
of 5.6% of which 5.5% were twins. Preterm delivery rate
was 16.6% (10.5% for singletons, 67.3% for twins and
92.3% for higher order multiples). Low birthweight was
reported in 12.7% of infants (6.7% for singletons follow-
ing SET and 7.3% following DET, 56.3% for twins and
97.4% for higher order multiples). Perinatal mortality
rate was 12.4 deaths per 1,000 births (Additional file 2).
In 2012 Canada reported that 27% of infants were
born from multigestational pregnancies, of which 26.3%
were twins and 1.1% were triplets [12]. For all ART pro-
cedures preterm delivery rates were 16.5% for singletons,
69.3% for twins and 100% for triplets. Low birthweight
was reported for 21% of infants (7.9% for singleton,
54.5% for twins and 96.2% for triplets). The total peri-
natal mortality rate was 1.0% per infant.
In 2012 among fresh autologous ART cycles the U.S.,
73% of live births were singletons, 26% were twins, and
1% were higher order multiples [17]. U.S. preterm deliv-
ery rates in 2012 fresh cycles were 11.1% for singletons,
17.4% for singletons from multiple pregnancies, 57.8%
for twins and 95.3% for higher order multiples. Low
birthweight was reported for 8.6% of singletons, 15.6%
for singletons from multiple fetal pregnancies, 56.1% for
twins and 92.3% for higher order multiples. Multiple-
infant births were particularly high among women under
age 35. In these young patients, 2012 U.S. data demon-
strate that live births were the highest (57%) following
DET, though the highest rates of singleton live births
were observed following SET.
In 2013 Latin America reported a multiple birth rate
of 21.8%, of which 20.7% were twins and 1.1% were
higher order multiples. Preterm births were reported for
7.5% of singleton, 36.6% of twin, and 65.5% of triplet
deliveries [16].
In 2011 Europe reported a multiple delivery rate of
19.2% in fresh ART cycles, of which 18.6% were twins
and 0.6% triplets. While in frozen-thawed ART cycles
the multiple delivery rate was 13.2% of which 12.8%
were twins and 0.4% triplets. The preterm delivery
rate for Europe was 12.0% for singletons, 53.9% for
twins and 91.4% for triplets [13]. For the U.K. it was
in all ART procedures 9.0% for singletons, 57.8% for
twins and 97.6% for triplets. In 2011 fresh autologous
ART cycles the U.K. reported a 20.6% multiple preg-
nancy rate [13, 14].
A detailed analysis of changes in Japanese perinatal
outcomes, associated with the country’s rapidly changing
ART practice patterns, was recently published [21]. In
2012, 96.0% of all ART pregnancies were singletons,
4.0% were twins and 0.05% were higher order multiples.
Low birthweight was recorded for 16.8% of infants con-
ceived with fresh embryos and 13.8% of those conceived
with frozen-thawed embryos. Since implementation of
an SET policy in 2008, rates of perinatal mortality de-
creased from 0.7 to 0.4% in fresh cycles but did not
change in frozen-thawed cycles, which now account for
most live birth in Japan. Preterm delivery rates also de-
creased between 2007 and 2012 from 13.5 to 9.4% in
pregnancies conceived with fresh embryos and from 12.7
to 9.6% in those conceived with frozen-thawed embryos.
Additionally, caesarian delivery rates decreased from
35.6% in 2007 to 32.8% in 2012 in fresh cycles but did
not change in frozen cycles [21].
Discussion
This review evaluated longitudinal data to gain insight
into ART practices and outcomes, and demonstrated
considerable disparities in live birth rates between re-
gions in the world. While over the last 10 years most re-
gions demonstrated improvement, some showed no
change and others demonstrated declines in ART live
birth rates.
These findings, of course, reflect major differences in
patient demographics, societal norms, local laws, and
economics, which impact ART practices and could not
be adjusted for in this analysis. Direct comparisons of
data from various regions are also subject to differences
in rigor of data reporting, collection and verification out-
lined above. Interpretations of here presented data
should, therefore, be made with caution, and in consid-
eration of these issues. The study is also somewhat in-
complete in that it does not include the Middle East,
large parts of Asia, and all of Africa. One Middle Eastern
country, Israel, on a per capita basis performs the high-
est number of ART cycles of any country in the world
[9]. We were unable to draw on appropriately published
ART data in any of these regions.
The U.S. maintained throughout the decade the high-
est fresh cycle live birth rates compared to other regions.
Continental Europe, however, for the first time appears
to have caught up to the US in its fresh cycle live birth
rates by 2010. The longstanding difference between US
and European outcomes has been subject of scrutiny by
European and US investigators [27–29]. A number of
reasons for the differences have been suggested, and in-
vestigators have in the past expressed strong opinions
on this subject. Confluence of U.S. and Continental
European fresh cycle live birth rates now suggest in-
creasing congruity of ART practice between the two
continents.
Newly integrated practices into ART to a large degree
involve methods of embryo selection, including
blastocyst-stage transfer, PGS, cryopreservation of all
embryos and subsequent frozen-thawed transfer, and the
utilization of SET. These new practices, however, may
not benefit all patient groups equally and in some,
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particularly poor prognosis patients, may, negatively
affect outcomes [30].
Live birth rates with frozen-thawed embryos im-
proved rapidly in the U.S. (Fig. 3b). Reported U.S. live
birth rates may be somewhat inflated due to exclusion
from national outcome reporting of embryo banking
cycles, some PGS cycles, and cycles where no em-
bryos are created for transfer or survive thaw to be
transferred [2, 26].
In some regions, live birth rates with frozen-thawed
embryos exceed those with fresh embryos. This might be
interpreted as evidence in support of routine embryo
banking in lieu of fresh transfer, [4, 31] especially since
efficiency of cryopreservation has improved with vitrifi-
cation. However, it more likely reflects differences in pa-
tient populations undergoing fresh versus frozen-thawed
embryo transfer. For example, younger and favorable
prognosis patients maybe more likely to have surplus
embryos for cryopreservation or banking and therefore
may be relatively overrepresented in frozen-thawed ver-
sus fresh cycles. Similarly, we have recently demon-
strated how patient selection biases in US national data
led CDC investigators to incorrect conclusions about
PGS effectiveness [32].
In 2004 Japan already demonstrated the lowest fresh
cycle live birth rates among all regions. Over the follow-
ing decade, Japan almost tripled its number of ART cy-
cles (Fig. 1a) and lost almost two-thirds of its fresh cycle
live births, dropping to a national rate of 5% by 2012
(Fig. 3a). The loss in fresh cycle live births was partially
compensated for by a relatively higher live birth rate in
frozen-thawed embryo transfer cycles, resulting in a rela-
tively stable annual total live birth rate (including fresh
and frozen-thawed cycles) as recently reported by Take-
shima et al [21]. Indeed, most ART infants in Japan in
recent years were conceived in frozen-thawed rather
than fresh ART cycles. Our findings along with those re-
ported by Takeshima et al. suggest that a large increase
in ART cycle volume was required to achieve a very
modest improvement in perinatal outcomes and offset
declining fresh cycle live birth rates.
No other region in the world demonstrated such rapid
change in ART practice. As such, it appears that changes
in national practice patterns in Japan, not equally experi-
enced in other regions in the world, led to the observed
outcome changes. For example, Teramoto and Kato pro-
posed minimal stimulation IVF and by 2007 reported
having performed 43,433 such cycles [7]. Similar proto-
cols have since been adopted by many Japanese ART
centers, and sporadically elsewhere [33–35]. The dra-
matic changes in Japanese ART cycle numbers and out-
comes, likely represent a combination of minimal
stimulation protocols, the potentially lower implantation
rate in fresh versus frozen-thawed transfers due to
endometrial factors, the fresh transfer of poor quality
embryos that may not go on to blastocyst-stage, progres-
sive migration to thawed embryo transfer, as well as, im-
plementation of stringent SET regulations [21].
Embryo selection efforts have also gained followers
elsewhere: For example, SET at blastocyst- stage has also
become a characteristic feature of ART in Australia/New
Zealand, [11, 36] areas of Canada [22] and in Northern
Europe [37, 38]. Australia/New Zealand reported already
in 2004 relatively low live birth rates in fresh ART cycles
which gradually further declined as utilization of SET at
blastocyst-stage increased (Fig. 3a). Australia and New
Zealand progressively shifted from cleavage- to blasto-
cyst- stage embryo transfers, with blastocyst-stage trans-
fers increasing from 49.8% in 2009 to 61.1% in 2013.
Concomitantly, fresh cycles that reached embryo transfer
in Australia and New Zealand decreased from 76.6 to
67.5% [11]. Likewise, data from Canada demonstrate a
decline in fresh cycle live birth rates following imple-
mentation of an SET mandate in the province of Quebec
in 2009 [23]. Increased utilization of SET, therefore, ap-
pears to be temporally associated with declines in fresh
cycle live birth rates. Regions with strict SET policies
have been able to lower their multiple delivery rates, for
example by 2012–2013 Australia/New Zealand and
Japan reported the lowest multiple delivery rates of 5.6%
and 4% while the US had the highest of 27%.
Utilization of elective SET is based on the premise
that twin pregnancies increase maternal and neonatal
outcome risks in comparison to singletons [39]. Our
group considers that a more appropriate way of fram-
ing the question in infertility patients is to compare
the outcome risks of two consecutive singleton preg-
nancies to one twin pregnancy [40, 41]. Moreover, it
is important to recognize that the risk profiles of
singleton and twin neonates vary greatly depending
on whether conception occurred spontaneously or via
ART [42, 43]. Nevertheless, to minimize risks of a
twin pregnancies, elective SET followed by a frozen-
thawed embryo transfer has in recent years been in-
creasingly offered to good prognosis patients, as this
approach is reported to produce a similar cumulative
pregnancy chance to DET [44]. It is also important to
note that we did not differentiate between elective
and non-elective SET in this review because this clas-
sification is typically not discernable in registry re-
ports. Patients undergoing non-elective SET are
typically those with poor prognosis or patients under-
going minimal stimulation IVF, both groups likely ex-
perience somewhat lower live birth rates than good
prognosis patients who are the best candidates for
elective SET [34, 44–46].
Pregnancy and live birth rates have been the trad-
itional metrics of ART success. More recently,
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investigators proposed that measures of neonatal health
should also be incorporated [47, 48]. As revealed in this
study, there are inconsistencies in the way perinatal out-
come data are presented by various registries, making
comparison between regions difficult. Further research
appears indicated to develop better perinatal outcome
associations with different ART practice patterns. More-
over, while most current ART registries present data per
cycle of treatment, efforts are now underway in
Australia/New Zealand and in the U.S. to link successive
treatment cycles undertaken by each female patient.
Therefore, ART registry reports may be evolving to de-
fine ART success as the birth of term, normal birth-
weight neonates per number of treated patients during
the calendar year.
Conclusion
In conclusion, our worldwide data analysis demonstrates
increasing utilization of ART, SET, and of frozen-thawed
embryos. Substantial differences in live birth rates exist
among various regions of the world. Since ART practices
affect different patient populations in varying ways, fur-
ther research is needed to better define individual prac-
tices in different patient populations. Concomitantly, the
profession should strive to achieve worldwide consensus
as to what metric(s) define(s) outcome success in associ-
ation with ART.
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